CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD.

Changchun High-tech Industry (Group) Co., Ltd. is a prominent manufacturing company based in China, primarily engaged in pharmaceutical manufacturing. Established in June 1993 and listed on the Shenzhen Stock Exchange in December 1996, the company has evolved from a focus on high-tech land infrastructure to a diversified enterprise group centered on medical science and technology innovation. With a commitment to corporate values that emphasize innovation and social responsibility, Changchun High-tech aims to create value for its customers, employees, and shareholders. The company's main business lines include genetic engineering pharmaceuticals, biological vaccines, and modern traditional Chinese medicine, supported by its real estate operations. Its subsidiaries, such as Changchun GeneScience Pharmaceuticals Co., Ltd., Changchun BCHT Biotechnology Co., Ltd., and Jilin Huakang Pharmaceutical Co., Ltd., hold leading positions in their respective segments. Changchun High-tech continues to enhance its market position through innovative projects and strategic partnerships, focusing on optimizing management and fostering a collaborative environment that values talent and knowledge.

Since from its listing, the Company, by the successful incubation of innovative projects, has primarily established its leading status in domestic genetic engineering pharmaceutics and biological vaccines fields. Holding subsidiaries of the Company: Changchun GeneScience Pharmaceuticals Co., Ltd., Changchun BCHT Biotechnology Co., Ltd. and Jilin Huakang pharmaceutical Co., Ltd. are taking the dominant positions in their own medicine subdivisions. The Company practices the development concept of “Innovation, Concentration, Generosity, Sharing”. It insists to take capital as the link and scientific innovation as the source power to adjust and optimize the management mode, build the innovative cooperation platform relying on bio-pharmaceuticals, assisted by featured real estate development and shared by parties. The Company keeps a foothold on “new mileage, new field of vision and new start” to further perfect and strengthen the five industrial plates: genetic engineering pharmaceuticals, biological vaccines, modern Chinese medicine, high-end generic drugs and gestured real estate. Focus of works on HR management of the Company relies on the building of a working environment of respecting knowledge, respecting talents and respecting personality. The concept of praising success and tolerating failure is the common sense of management and entrepreneur/innovator. The Company will expand channels and develop multiple measures to employ people according to their merits with the cultural concept of tolerance.